Therefore, NSCLC therapies underwent an innovative transformation when it was realized that the mutant status of epidermal growth factor receptor (EGFR) directly affected the effectiveness of EGFR TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.